Zomedica Corp. provided earnings guidance for the fourth quarter and year ended 2022. For the quarter, revenue is expected to be approximately $6.0 million-$6.2 million, an increase of 46%-51% compared to the same prior year period, primarily driven by an increase in PulseVet sales and the inclusion of its recently acquired Assisi products.

For the year, revenue is expected to be approximately $18.6 million-$18.9 million, an increase of 354%-361% compared to the same prior year period, primarily driven by a full year's worth of PulseVet sales and the inclusion of its recently acquired Assisi products.